Novelion Therapeutics Observes Rare Disease Day
28 févr. 2019 07h00 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of...
Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
06 févr. 2019 02h30 HE
|
Novelion Therapeutics, Inc.
Out-licensing of commercialization rights allows for significant operating expense savingsUpfront payments improve near-term liquidity VANCOUVER, British Columbia, Feb. 06, 2019 (GLOBE NEWSWIRE) --...
Novelion Therapeutics Announces Leadership Change
20 nov. 2018 16h05 HE
|
Novelion Therapeutics, Inc.
Novelion General Counsel Benjamin Harshbarger Appointed as Interim Chief Executive Officer (CEO) VANCOUVER, British Columbia, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics...
Novelion Therapeutics Reports Third Quarter 2018 Financial Results
09 nov. 2018 08h46 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for...
Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update
08 nov. 2018 08h48 HE
|
Novelion Therapeutics, Inc.
- New Aegerion loan facility, provided by existing bondholders, strengthens balance sheet and is expected to provide bridge to a potential comprehensive long-term capital restructuring - Company...
Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
24 sept. 2018 08h30 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of...
Novelion Therapeutics Announces Next Phase of Operational Improvements
23 août 2018 07h43 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals...
Novelion Therapeutics Reports Second Quarter 2018 Financial Results
07 août 2018 08h30 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for...
Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
31 juil. 2018 08h15 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, July 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to delivering new standards of care for people living...
Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors
03 juil. 2018 08h30 HE
|
Novelion Therapeutics, Inc.
VANCOUVER, British Columbia, July 03, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) today announced that Mark Corrigan, M.D. has been appointed as Executive Chair of the Board of...